Acticor Biotech SAS provided an update on the progress of its clinical programs with glenzocimab, its lead drug candidate. ACTISAVE: Phase 2/3 clinical study in stroke Study design and regulatory discussions ACTISAVE (NCT05070260) is a multinational, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. The study is being conducted in 7 European countries, UK, Israel, and the USA.

The European Medicines Agency (EMA) approved the adaptive design strategy and validated the choice of a dual primary endpoint: an ordinal endpoint of the difference between the Modified Rankin Scale (mRS)1 and a binary endpoint of the percentage of patients with severe disability or death, i.e. an mRS score of 4-6 The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe. n the context of the "PRIME" status received in July 2022, a program aimed at optimizing the development plan to speed up patient access to the drug candidate, the company is continuing its interactions with the EMA. In the United States, discussions are underway with the American regulatory agency (FDA) to set up a Type C meeting to validate the design and statistical analysis of the study in support of a future Biologic License Application (BLA) in the United States.

An amendment to the study protocol allowing the use of the two recognized thrombolytic agents in stroke management, tenecteplase (TNK) and alteplase, was submitted to the FDA in November 2022, and is awaiting approval by the Ethics Review Board (IRB). Two patients have been enrolled to date. This amendment should accelerate enrollment, given the massive use of TNK in U.S. hospitals.

Number of patients recruited to date: 203 patients. Next clinical step: an initial futility analysis is planned when 100 patients will be enrolled with thrombolysis + thrombectomy, treated and followed for 90 days to confirm the safety of the study and ensure that the preliminary results are consistent with the original trial assumptions. Results of this futility study are expected in the 3rd quarter 2023.

2. GREEN: Phase 2/3 clinical trial in stroke Study design GREEN (NCT05559398) is a randomized, double-blind, multicenter, placebo-controlled Phase 2/3 study of the efficacy and safety of glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke. The GREEN study is conducted under the auspices of the Paris Public Hospitals (Assistance Publique û H(pitaux de Paris), and is part of the RHU BOOSTER, receiving financial support from the French National Research Agency (Agence Nationale de la Recherche) and the GovernmentÆs æInvestments for the FutureÆ program (Programme Investissements dÆAvenir). The primary objective of this study is to evaluate the efficacy of glenzocimab in combination with endovascular thrombectomy (EVT) versus EVT alone on 90-day functional outcome (mRS).

Secondary objectives are to evaluate the impact of glenzocimab on overall survival, reperfusion, clinical improvement at 24 hours, symptomatic and asymptomatic intracerebral hemorrhage, serious adverse events (SAEs), serious unexpected adverse events (SUSARs) and quality of life. This study will include nearly 260 patients eligible for mechanical thrombectomy in 11 French neurovascular units and institutions of excellence. Number of patients recruited to date: 1 patient.

Next clinical step: an interim analysis will be performed after the first 78 patients are included and is expected end of 2023. 3) LIBERATE: Phase 2b clinical trial in the treatment of myocardial infarction Study design LIBERATE (IRAS -1005400) is a randomized, double-blind, Phase 2b study that will include more than 200 patients in the acute phase of myocardial infarction to test the safety and efficacy of glenzocimab 1000 mg versus placebo in reducing cardiac damage remote from the infarction. This study is being conducted in partnership with the University of Birmingham (UK), with expert clinicians from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust.

Current status of the study: file being submitted to the UK regulatory authorities. Next clinical step: Inclusion of the first patient planned for the second quarter of 2023. 4. Other indications for cardiovascular emergencies At this stage of development, Acticor Biotech has decided to focus its efforts on the development of glenzocimab in stroke and myocardial infarction with three ongoing studies (ACTISAVE, GREEN and LIBERATE) and to postpone the launch of its Phase 2 study, BREATHE in pulmonary embolism.